Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body
Biofrontera Inc. (NASDAQ: BFRI) submitted a supplemental New Drug Application to the FDA to expand Ameluz®'s use for treating actinic keratoses (AKs) to the full body, beyond the face and scalp. The submission follows a 12% revenue growth in 2025 and a 25% increase in the first half of 2026. The application is supported by clinical trial data showing 45.6% complete clearance of AK lesions. If approved, Ameluz® would be the only PDT approved in the U.S. for full-body AK treatment.
How this was made
The 30-second read
Why it matters
The sNDA expands the addressable patient pool from face/scalp to full-body AKs, potentially increasing sales volume significantly.
Market read
Regulatory progress for a niche dermatology drug could drive short-term stock movement and longer-term revenue outlook.
What to watch
Reimbursement landscape and competition from other AK treatments could limit upside
Background
Biofrontera recently received FDA approval for Ameluz® in superficial basal cell carcinoma, positioning it for further label expansions.
Ticker impact
Biofrontera submitted a supplemental NDA to the FDA to expand Ameluz® to full-body actinic keratoses, a new regulatory filing.
likely upward pressure as investors price in possible label expansion
Regulatory filing is a primary catalyst; market typically reacts positively to expanded indications for niche dermatology drugs.
Market effects
could boost sentiment for dermatology and photodynamic therapy stocks
U.S. biotech sector may see modest lift
limited to companies with similar dermatology pipelines
Counterpoint
Approval risk remains high; FDA may request additional data, causing downside if delayed
Key entities
- companyBiofrontera Inc.
U.S.-based biopharma developing photodynamic therapy products.
- regulatorFDA
U.S. Food and Drug Administration reviewing the supplemental NDA.
